Cancer is a complex disease, and its treatment is a big challenge, with variable efficacy of
conventional anticancer drugs. A two-drug cocktail hybrid approach is a potential strategy in …

Advanced stages of cancer are highly associated with short overall survival in patients due
to the lack of long-term treatment options following the standard form of care. New options …

PARP inhibitors are the first clinically approved drugs that were developed based on
synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical …

Amongst heterocyclic compounds, quinoline and its derivatives are advantaged scaffolds
that appear as a significant assembly motif for developing new drug entities. Aminoquinoline …

Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …

A series of new heterocycle hybrids incorporating pyrazole and isoxazoline rings was
successfully synthesized, characterized, and evaluated for their antimicrobial responses …

Cancer, a noncommunicable disease, is the leading cause of mortality worldwide and is
anticipated to rise by 75% in the next two decades, reaching approximately 25 million cases …

Abstract 3, 4, 5-Trimethoxy-3′-hydroxy-4′-methoxystilbene (TMHMS) is an anticancer
natural stilbene that targets tubulin polymerization. According to research, oxidative stress …

A potent natural combretastatin, combretastatin A-4 (COMA4) targets the condylon active
pocket to produce anticancer effects. Studies on inflammation and oxidative stress have …

One of the main current strategies for cancer treatment is represented by combination
chemotherapy. More recently, this strategy shifted to the “hybrid strategy”, namely the …